ArticleArchives of academic emergency medicine2025
Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial.
Article in Archives of academic emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lead poisoning can present with a spectrum of symptoms, from fatigue to severe multiorgan complication; and Zeolite is known for its ability to remove heavy metals. This study aimed to assess the impact of zeolite on serum lead levels and blood parameters of patients with mild to moderate lead poisoning. Methods: This double-blind randomized clinical trial evaluated the effects of zeolite on serum lead levels of patients with mild to moderate lead poisoning, conducted between August 2022 and December 2022. The intervention group received oral zeolite tablets in addition to standard treatment, while the control group received only standard treatment. The impact of zeolite administration on serum lead levels and blood parameters was investigated using an appropriate statistical test. Results: 80 patients with a mean age of 39.84 ± 11.94 (range: 23-75) years were randomized (78.75% male). The two groups were similar regarding age (p = 0.329), sex (p = 0.785), baseline serum lead levels (p = 0.596), and liver enzymes (p = 0.648).The Zeolit group had lower serum lead levels (25.22 ± 13.26 vs. 37.68 ± 15.34; p < 0.001, ES: 0.869) and hematocrit (36.21 ± 7.83 vs. 39.53 ± 5.60; ES: 0.488; p = 0.032) after 2 weeks of treatment. Conclusion: Zeolite tablets show considerable promise as an adjunct therapy for mild to moderate lead poisoning. They effectively lower serum lead levels without adverse effects. This intervention could reduce the metal burden in the bloodstream and mitigate lead-induced multiorgan damage, offering a more effective and less invasive treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.